- Home
- ANY vs BLRX Comparison
ANY vs BLRX Comparison
Compare ANY & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANY
- BLRX
- Stock Information
- Founded
- ANY N/A
- BLRX 2003
- Country
- ANY United States
- BLRX Israel
- Employees
- ANY N/A
- BLRX N/A
- Industry
- ANY Finance: Consumer Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ANY Finance
- BLRX Health Care
- Exchange
- ANY Nasdaq
- BLRX Nasdaq
- Market Cap
- ANY 16.4M
- BLRX 17.2M
- IPO Year
- ANY N/A
- BLRX 2011
- Fundamental
- Price
- ANY $0.70
- BLRX $3.83
- Analyst Decision
- ANY Strong Buy
- BLRX Strong Buy
- Analyst Count
- ANY 1
- BLRX 2
- Target Price
- ANY $3.00
- BLRX $19.00
- AVG Volume (30 Days)
- ANY 552.0K
- BLRX 32.7K
- Earning Date
- ANY 11-13-2025
- BLRX 08-14-2025
- Dividend Yield
- ANY N/A
- BLRX N/A
- EPS Growth
- ANY N/A
- BLRX N/A
- EPS
- ANY N/A
- BLRX N/A
- Revenue
- ANY $10,831,000.00
- BLRX $17,251,000.00
- Revenue This Year
- ANY N/A
- BLRX N/A
- Revenue Next Year
- ANY $36.07
- BLRX N/A
- P/E Ratio
- ANY N/A
- BLRX N/A
- Revenue Growth
- ANY N/A
- BLRX 1.19
- 52 Week Low
- ANY $0.36
- BLRX $2.30
- 52 Week High
- ANY $1.90
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- ANY 61.14
- BLRX 49.75
- Support Level
- ANY $0.66
- BLRX $3.68
- Resistance Level
- ANY $0.73
- BLRX $4.11
- Average True Range (ATR)
- ANY 0.05
- BLRX 0.25
- MACD
- ANY 0.01
- BLRX 0.03
- Stochastic Oscillator
- ANY 70.84
- BLRX 43.77
About ANY Sphere 3D Corp.
Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Bitcoin Mining and Service and Product. The Bitcoin Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.